Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
572 hedge funds and large institutions have $22B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2021 Q3 according to their latest regulatory filings, with 87 funds opening new positions, 211 increasing their positions, 196 reducing their positions, and 38 closing their positions.
287% more call options, than puts
Call options by funds: $396M | Put options by funds: $102M
129% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 38
20% more funds holding in top 10
Funds holding in top 10: 25 → 30 (+5)
17% more capital invested
Capital invested by funds: $18.8B → $22B (+$3.26B)
9% more funds holding
Funds holding: 526 → 572 (+46)
8% more repeat investments, than reductions
Existing positions increased: 211 | Existing positions reduced: 196
Top Buyers
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$212M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$82M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$69.8M |
| 4 |
Morgan Stanley
New York
|
+$52.9M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$50.8M |
Top Sellers
HZNP Hedge Fund Activity: Q3 2021 in Review
572 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2021, worth a combined $22B — up 17% from $18.8B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new HZNP positions and 38 closed out — a net gain of 49 holders — while 211 added to existing stakes and 196 trimmed.
The largest buyer was Nuveen, adding an estimated $212M. The largest seller was Paulson & Co, cutting an estimated $189M.
- 572 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2021, up from 526 in Q2 2021.
- Funds reported $22B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2021, up 17% quarter-over-quarter.
- 87 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2021 and 38 closed out, a net change of +49 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2021 was Nuveen, an estimated $212M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2021 was Paulson & Co, an estimated $189M sold.
Based on aggregated 13F filings for Q3 2021.